Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in HIV-associated dyslipidemia
2015-004735-12Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia, combined dyslipidaemia and hyperlipidemia comparing Evolocumab monthly with Placebo monthly (2 arms). Primary endpoint: Percent change from baseline in LDL cholesterol at week 24. Started Jun 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacombined dyslipidaemiahyperlipidemia
Beyond the preview
Go deeper on 2015-004735-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004735-12.